<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.103050</article-id><article-id pub-id-type="publisher-id">ACM-34700</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200300000_78822160.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  糖尿病视网膜病变发病机制研究
  Study on the Pathogenesis of Diabetic Retinopathy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>常</surname><given-names>静</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>理论</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>贺</surname><given-names>经</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>延安大学附属医院眼科，陕西 延安</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>03</month><year>2020</year></pub-date><volume>10</volume><issue>03</issue><fpage>315</fpage><lpage>319</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   糖尿病视网膜病变是工业化国家人口视力受损的主要原因。虽然视网膜神经功能的损伤发生在血管病变之前已经被证实，但是最常见的早期临床表现还是微动脉瘤和视网膜内出血。微血管损伤导致视网膜毛细血管的无灌注、棉绒斑、出血点的数量增加、静脉异常、视网膜微血管异常。在这个阶段期间，视网膜血管的通透性增加可以导致视网膜厚度的增加和视网膜渗出物的渗出，最终导致中心视力的下降。增殖期，视网膜动静脉闭塞，视盘、视网膜、虹膜及房角形成新生血管。这些新生血管导致牵拉性视网膜脱离和新生血管性青光眼。这时毛细血管的无灌注或黄斑处的水肿，玻璃体积血和血管扭曲及牵拉性视网膜脱离都可导致视力的丧失。 Objective: Diabetic retinopathy is the main cause of visual impairment in the population of indus-trialized countries. Although damage to retinal nerve function has been confirmed before vascular lesions, the most common early clinical manifestations are microaneurysms and intraretinal hemorrhage. Microvascular damage leads to retinal capillaries, no perfusion of blood vessels, cotton wool spots, an increase in the number of bleeding points, venous abnormalities, and retinal microvascular abnormalities. During this phase, increased permeability of retinal blood vessels can lead to increased retinal thickness and retinal exudate exudation, eventually Lead to decreased central vision. During the proliferative phase, retinal arteriovenous occlusion, new blood vessels are formed in the optic disc, retina, iris, and atrial angle. These new blood vessels cause tractional retinal detachment and neovascular glaucoma. No capillary perfusion or macular at this time Edema at the site, vitreous hemorrhage, blood vessel distortion, and traction retinal detachment can all lead to vision loss. 
 
</p></abstract><kwd-group><kwd>糖尿病，糖尿病视网膜病变，发病机制, Diabetes</kwd><kwd> Diabetic Retinopathy</kwd><kwd> Pathogenesis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>糖尿病视网膜病变发病机制研究<sup> </sup></title><p>常静，王理论，贺经</p><p>延安大学附属医院眼科，陕西 延安</p><p>收稿日期：2020年3月2日；录用日期：2020年3月17日；发布日期：2020年3月24日</p><disp-formula id="hanspub.34700-formula222"><graphic xlink:href="//html.hanspub.org/file/24-1571198x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>糖尿病视网膜病变是工业化国家人口视力受损的主要原因。虽然视网膜神经功能的损伤发生在血管病变之前已经被证实，但是最常见的早期临床表现还是微动脉瘤和视网膜内出血。微血管损伤导致视网膜毛细血管的无灌注、棉绒斑、出血点的数量增加、静脉异常、视网膜微血管异常。在这个阶段期间，视网膜血管的通透性增加可以导致视网膜厚度的增加和视网膜渗出物的渗出，最终导致中心视力的下降。增殖期，视网膜动静脉闭塞，视盘、视网膜、虹膜及房角形成新生血管。这些新生血管导致牵拉性视网膜脱离和新生血管性青光眼。这时毛细血管的无灌注或黄斑处的水肿，玻璃体积血和血管扭曲及牵拉性视网膜脱离都可导致视力的丧失。</p><p>关键词 :糖尿病，糖尿病视网膜病变，发病机制</p><disp-formula id="hanspub.34700-formula223"><graphic xlink:href="//html.hanspub.org/file/24-1571198x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/24-1571198x7_hanspub.png" /> <img src="//html.hanspub.org/file/24-1571198x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>长期慢性高血糖症和相应的糖毒性诱导并增强炎症是糖尿病病人微血管并发症的发病基础。其中眼部的并发症为糖尿病视网膜病变(DR)，目前关于糖尿病视网膜病变的微血管病变的发病机制包括：多元醇途径、己糖胺途径、蛋白激酶途径(PKC)活化、晚期糖基化终产物(AGE)的形成、血管紧张素II (ANG-II)诱发视网膜氧化损伤 [<xref ref-type="bibr" rid="hanspub.34700-ref1">1</xref>]。</p></sec><sec id="s4"><title>2. 晚期糖基化终产物(AGE)的形成(Advanced glycation end product formation)</title><p>在高血糖条件下积累的AGEs被认为在糖尿病的微血管和大血管并发症(包括视网膜病变，神经变性，肾病以及动脉粥样硬化)中起着致病性的作用 [<xref ref-type="bibr" rid="hanspub.34700-ref2">2</xref>]。AGEs的长期沉积已通过多种机制被证明对细胞和组织有害 [<xref ref-type="bibr" rid="hanspub.34700-ref3">3</xref>]。AGEs与细胞外基质关键分子之间的异常交联导致血管壁弹性降低，管壁变硬，从而增加了血管壁的厚度和硬度 [<xref ref-type="bibr" rid="hanspub.34700-ref4">4</xref>]。此外，AGEs与不同细胞受体的结合可以触发多种细胞信号通路。RAGE是最早发现的，也是迄今为止研究最多的AGEs受体。它是一种35 kDa的免疫球蛋白超家族蛋白，主要用作多个分子的多配体跨膜结合剂。RAGE定位于眼球中的各种细胞类型中，例如巨噬细胞，单核细胞，内皮细胞(EC)，平滑肌细胞和肝细胞，它在血管内皮细胞，周细胞，小胶质细胞，M&#252;ller胶质细胞和视网膜色素上皮(RPE)细胞，其表达在糖尿病条件下显著增加 [<xref ref-type="bibr" rid="hanspub.34700-ref5">5</xref>]。与RAGE结合的AGEs诱导了多种下游途径的激活，例如p21ras和丝裂原激活的蛋白激酶(MAPKs)途径，随后核因子-κB (NF-κB)易位，生长因子，促炎性细胞因子以及粘附分子最终导致细胞功能紊乱 [<xref ref-type="bibr" rid="hanspub.34700-ref6">6</xref>]。进而导致毛细血管周细胞的凋亡、血管内皮功能障碍、炎性因子增多、促血管生成因子(VEGF)的增多，临床症状表现为微血管瘤的形成、出血点、棉绒斑、硬性渗出、新生血管等表现。</p></sec><sec id="s5"><title>3. 多元醇途径(Polyol pathway)</title><p>多元醇途径也称为山梨糖醇-醛糖还原酶途径，是将高血糖症和糖尿病视网膜病变联系起来的主要途径之一 [<xref ref-type="bibr" rid="hanspub.34700-ref7">7</xref>]。当体内血糖长期慢性升高时，葡萄糖代谢的多元醇通路开始活跃，醛糖还原酶(AR)是该途径中的第一个酶同时也是限速酶，它利用NADPH作为辅因子将葡萄糖还原为山梨糖醇。然后，使用NAD+作为辅因子的山梨糖醇脱氢酶将山梨糖醇代谢为果糖。而山梨糖醇是一种多羟基化的醇，具有很强的亲水性，因此不易在细胞膜中扩散，并在细胞内蓄积，可能导致渗透作用 [<xref ref-type="bibr" rid="hanspub.34700-ref8">8</xref>]。由多元醇途径产生的果糖可被磷酸化成果糖-3-磷酸，最终被降解为3-脱氧葡萄糖酮，这两种化合物都是强大的糖基化剂，都可参与晚期糖基化终产物(AGEs)的形成 [<xref ref-type="bibr" rid="hanspub.34700-ref9">9</xref>]。同时醛糖还原酶(AR)也可降低细胞对氧化应激的反应能力因为醛糖还原酶对NADPH的使用可能会减少可用于谷胱甘肽(GSH)还原酶的辅因子，但这些辅因子对于维持细胞内的还原型谷胱甘肽至关重要。此时细胞内会代偿性的活化NADPH的主要提供者1-磷酸葡萄糖的分流。山梨醇脱氢酶使用NAD将会导致NADPH/NAD+的比例增加，这个过程又被称为“假性缺氧”，这与已知的改变细胞功能的多种代谢和信号通路有关 [<xref ref-type="bibr" rid="hanspub.34700-ref10">10</xref>]。因此，通过改变细胞内张力，产生AGEs前体以及使细胞暴露于氧化应激(可能是通过降低抗氧化剂的防御力和氧化剂种类的产生)来激活多元醇途径，可以引发并增加细胞损伤的几种机制。</p></sec><sec id="s6"><title>4. 己糖胺途径(Hexosamine pathway)</title><p>大量的葡萄糖被磷酸化后生成果糖-6-磷酸，果糖-6-磷酸又被果糖-6-磷酸氨基转移酶(GFAI)催化生成氨基葡萄糖-6-磷酸。谷氨酰胺通过给葡萄糖提供氨基生成果糖-6-磷酸。氨基葡萄糖-6-磷酸也可被N-乙酰氨基葡萄糖异构化和乙酰化后生成。同时葡萄糖胺也可被己糖激酶磷酸化后生成氨基葡萄糖-6-磷酸。大量的氨基葡萄糖-6-磷酸可转化生成二磷酸尿嘧啶N-乙酰氨基葡萄糖(UDP-GLCNAC)，二磷酸尿嘧啶N-乙酰氨基葡萄糖(UDP-GLCNAC)正是细胞内因子转录后修饰底物，结果可以造成甘油、糖脂、糖蛋白的生成。此外，己糖胺途径还可以调节氧化应激(ROS)的毒性作用 [<xref ref-type="bibr" rid="hanspub.34700-ref11">11</xref>]。在长期慢性的高血糖下，视网膜细胞内发生氧化应激反应，这种氧化应激反应可抑制甘油醛-3-磷酸脱氢酶GAPDH的活性，与此同时糖酵解途径的活性增强，糖酵解的产物进入己糖胺途径，生成葡萄糖胺，葡萄糖胺进一步生成H<sub>2</sub>O<sub>2</sub>，增多的H<sub>2</sub>O<sub>2</sub>产物促进细胞内的氧化应激反应增强，最后使得内皮细胞发生改变、毛细血管的管壁渗透性增加、新生血管生成 [<xref ref-type="bibr" rid="hanspub.34700-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.34700-ref13">13</xref>]。与此同时，被抑制的甘油醛-3-磷酸脱氢酶GAPDH的活性也会在细胞内丙酮醛的作用下使得晚期糖基化终产物(AGEs)的生成增多，从而进一步加强氧化应激反应 [<xref ref-type="bibr" rid="hanspub.34700-ref13">13</xref>]。</p></sec><sec id="s7"><title>5. 蛋白激酶途径PKC活化(Protein kinasec activation)</title><p>蛋白激酶途径PKC活化是糖尿病视网膜病变机制中最为重要的机制，活化的PKC通路可以增加视网膜血管内皮的通透性来损伤内皮细胞、改变NO的生物利用度、减少前列腺素的产生、诱导VEGF表达、诱导产生血栓素和内皮素-1(EF-1)。PKC代表一个由依赖于DAG和Ca<sup>2+</sup>激活的亚型组成的激酶家族。这些家族分为α、βI、βII和依赖Ca<sup>2+</sup>和DAG的γ。另一个家族分为δ、ε、η和θ。这些不依赖Ca<sup>2+</sup>，但是依赖DAG [<xref ref-type="bibr" rid="hanspub.34700-ref14">14</xref>]。当视网膜细胞长期处在慢性高血糖的环境下，导致ROS积累、甘酰甘油(DAG)合成激活PKC通路，同时PKC家族的亚型PKC-α、PKC-β、PKC-γ、PKC-δ、PKC-ε也被激活。而PKC-β的激活可以诱发在血管内皮内NO、EF-1、VEGF的释放，使得视网膜血管的通透性增大，血管血流量减少，最终导致黄斑水肿。而PKC-δ可以诱导ROS的形成，激活P38和丝裂原活化蛋白激酶(MAPK)通路，而丝裂原活化蛋白激酶途径是一组能被不同的细胞外环境刺激，如细胞因子、神经递质、激素、细胞应激及细胞黏附等激活的丝氨酸-苏氨酸蛋白激酶，大多数MAPK实际上参与对潜在有害的非生物应激刺激(高渗透压、氧化应激、DNA损伤、低渗透压)的反应。而p38则介导炎症、凋亡等。所以P38和MAPK通路使得SHP-1基因和NF-kB表达，一方面它们可抑制血小板衍生生长因子(PDGF)的表达，另一方面也可以激活caspase信号通路，最终导致视网膜血管壁上的周细胞凋亡进而形成微血管瘤。PKC通路也可通过eNOS基因表达改变NO的产生影响视网膜血管的张力和血管的通透性，从而造成血管内皮功能障碍 [<xref ref-type="bibr" rid="hanspub.34700-ref15">15</xref>]。</p></sec><sec id="s8"><title>6. 血管紧张素II (ANG-II)诱发视网膜氧化损伤</title><p>在糖尿病中，肾素血管紧张素系统(RAS)的成分在包括视网膜在内的几个组织中都有系统和局部的增加。血管紧张素II (Ang-II)是肾素-血管紧张素系统(RAS)的产物，参与调节血压、体液、电解质平衡，并在系统和细胞水平上影响稳态，然而在糖尿病人的视网膜中Ang-II水平升高在激活炎症、氧化应激、神经变性和内皮功能障碍中起致病作用，这可能导致DR。许多研究表明Ang-II在动脉粥样硬化和糖尿病的发病机制中起着重要的作用。其中在糖尿病视网膜病变中Ang-II会导致视网膜血管发生收缩、炎症反应、氧化应激反应、血管内皮细胞功能障碍、新生血管形成和血管的纤维化 [<xref ref-type="bibr" rid="hanspub.34700-ref16">16</xref>]。还有研究证实Ang-II可以激活NADPH酶的水平，增加ROS的产物，进而损伤内皮细胞。</p></sec><sec id="s9"><title>7. 小结</title><p>DR的血管病变机制复杂多样，研究和阐明DR血管病变的发病机制对于DR的临床前期的早诊断、早治疗具有深远的意义。</p></sec><sec id="s10"><title>8. 展望</title><p>虽然DR的病因机制尚不明确，目前对于DR的治疗主要是以视网膜激光光凝术、玻璃体药物注射术、视网膜玻璃体切除术为主，但是这些治疗手段均可不同程度地损害视网膜功能，进一步研究阐明DR发病机制，DR早期采取预防性的措施，延缓DR的进展，对于DR的治疗至关重要。</p></sec><sec id="s11"><title>文章引用</title><p>常 静,王理论,贺 经. 糖尿病视网膜病变发病机制研究Study on the Pathogenesis of Diabetic Retinopathy[J]. 临床医学进展, 2020, 10(03): 315-319. https://doi.org/10.12677/ACM.2020.103050</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.34700-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">McCance, D.R., et al. (1993) Maillard Reaction Products and Their Relation to Complications in Insulin-Dependent Diabetes Mellitus. Journal of Clinical Investigation, 91, 2470-2478. &lt;br&gt;https://doi.org/10.1172/JCI116482</mixed-citation></ref><ref id="hanspub.34700-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kandarakis, S.A., et al. (2014) Emerging Role of Advanced Glycation-End Products (AGEs) in the Pathobiology of Eye Diseases. Progress in Retinal and Eye Research, 42, 85-102. &lt;br&gt;https://doi.org/10.1016/j.preteyeres.2014.05.002</mixed-citation></ref><ref id="hanspub.34700-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, W.J., et al. (2017) Role of Moesin, Src, and ROS in Advanced Glycation End Product-Induced Vascular Endothelial Dysfunction. Microcirculation, 24. &lt;br&gt;https://doi.org/10.1111/micc.12358</mixed-citation></ref><ref id="hanspub.34700-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chen, M., Curtis, T.M. and Stitt, A.W. (2013) Advanced Glycation End Products and Diabetic Retinopathy. Current Medicinal Chemistry, 20, 3234-3240. &lt;br&gt;https://doi.org/10.2174/09298673113209990025</mixed-citation></ref><ref id="hanspub.34700-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Milne, R. and Brownstein, S. (2013) Advanced Glycation End Products and Diabetic Retinopathy. Amino Acids, 44, 1397-1407. &lt;br&gt;https://doi.org/10.1007/s00726-011-1071-3</mixed-citation></ref><ref id="hanspub.34700-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mishra, B., Swaroop, A. and Kandpal, R.P. (2016) Genetic Components in Diabetic Retinopathy. Indian Journal of Ophthalmology, 64, 55-61. &lt;br&gt;https://doi.org/10.4103/0301-4738.178153</mixed-citation></ref><ref id="hanspub.34700-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Gabbay, K.H. (1973) The Sorbitol Pathway and the Complications of Diabetes. The New England Journal of Medicine, 288, 831-836. &lt;br&gt;https://doi.org/10.1056/NEJM197304192881609</mixed-citation></ref><ref id="hanspub.34700-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Szwergold, B.S., Kappler, F. and Brown, T.R. (1990) Iden-tification of Fructose 3-Phosphate in the Lens of Diabetic Rats. Science, 247, 451-454. &lt;br&gt;https://doi.org/10.1126/science.2300805</mixed-citation></ref><ref id="hanspub.34700-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Luo, X., et al. (2016) Hyperglycemic Stress and Carbon Stress in Diabetic Glucotoxicity. Aging and Disease, 7, 90-110. &lt;br&gt;https://doi.org/10.14336/AD.2015.0702</mixed-citation></ref><ref id="hanspub.34700-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Jones, D.R., et al. (2014) The Hexosamine Biosynthesis Pathway and O-GlcNAcylation Maintain Insulin-Stimulated PI3K-PKB Phosphorylation and Tumour Cell Growth after Short-Term Glucose Deprivation. The FEBS Journal, 281, 3591-3608. &lt;br&gt;https://doi.org/10.1111/febs.12879</mixed-citation></ref><ref id="hanspub.34700-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Altmann, C. and Schmidt, M. (2018) The Role of Microglia in Diabetic Retinopathy: Inflammation, Microvasculature Defects and Neurodegeneration. International Journal of Molecular Sciences, 19, E110. &lt;br&gt;https://doi.org/10.3390/ijms19010110</mixed-citation></ref><ref id="hanspub.34700-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Beisswenger, P.J., et al. (2003) Glyceraldehyde-3-phosphate Dehy-drogenase Activity as an Independent Modifier of Methylglyoxal Levels in Diabetes. Biochimica et Biophysica Acta, 1637, 98-106. &lt;br&gt;https://doi.org/10.1016/S09254439(02)00219-3</mixed-citation></ref><ref id="hanspub.34700-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Volpe, C., et al. (2018) Cellular Death, Reactive Oxygen Species (ROS) and Diabetic Complications. Cell Death &amp; Disease, 9, 119. &lt;br&gt;https://doi.org/10.1038/s41419-017-0135-z</mixed-citation></ref><ref id="hanspub.34700-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Yokota, T., et al. (2003) Role of Protein Kinase C on the Ex-pression of Platelet-Derived Growth Factor and Endothelin-1 in the Retina of Diabetic Rats and Cultured Retinal Ca-pillary Pericytes. Diabetes, 52, 838-845. &lt;br&gt;https://doi.org/10.2337/diabetes.52.3.838</mixed-citation></ref><ref id="hanspub.34700-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Lai, T.H., Wu, P.H. and Wu, W.B. (2016) Involvement of NADPH Oxidase and NF-kappaB Activation in CXCL1 Induction by Vascular Endothelial Growth Factor in Human Endometrial Epithelial Cells of Patients with Adenomyosis. Journal of Reproductive Immunology, 118, 61-69. &lt;br&gt;https://doi.org/10.1016/j.jri.2016.08.011</mixed-citation></ref><ref id="hanspub.34700-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Drummond, G.R. and Sobey, C.G. (2014) Endothelial NADPH Oxidases: Which NOX to Target in Vascular Disease? Trends in Endocrinology and Metabolism, 25, 452-463. &lt;br&gt;https://doi.org/10.1016/j.tem.2014.06.012</mixed-citation></ref></ref-list></back></article>